This work quantified free form topotecan in human plasma, plasma ultrafiltrate, urine, and tissue homogenate samples from patients dosed with liposomal formulated topotecan. Each matrix had individualized sensitivity, stability, and sample handling requirements to preserve the free and liposomal forms during collection and analysis. 

An interdependent workflow approach was taken for each method to be optimized in tandem.

Download this poster to explore the methods, results, and conclusions of this study.